Generic drug
Cyclosporine price, strengths & recalls
Generic of Neoral, Restasis, Cequa, Gengraf, Vevye
Pharmacies pay $27.24 for 30 vials of Cyclosporine 0.5 mg/mL, 0.4 mL eye drops (suspension) this week, and from $9.93 to $222.14 across its 7 priced strengths and forms. 14 manufacturers make it. 4 recalls are ongoing. Its official label last changed on November 9, 2026.
4 open recallsGeneric- Fair cash price
- $41.83
- Strengths
- 7
- Makers
- 14
- Updated
- Nov 11
Cyclosporine price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 25 mg capsule | $2.51 | $75.40 / 30 capsules |
| 25 mg capsule | $0.3309 | $9.93 / 30 capsules |
| 50 mg capsule | $0.8152 | $24.46 / 30 capsules |
| 100 mg capsule | $1.25 | $37.65 / 30 capsules |
| 100 mg capsule | $7.40 | $222.14 / 30 capsules |
| 0.5 mg/mL, 0.4 mL eye drops (suspension) | $0.9081 | $27.24 / 30 vials |
| 100 mg/mL oral solution | $2.02 | $101.20 / 50 mL |
The lowest cost per capsule is 25 mg capsule at $0.3309. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of cyclosporine
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 28 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Cyclosporine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filled Cyclosporine Capsules, USP (MODIFIED) (Soft Gelatin Capsules) Rx only Prescribing Information
WARNING
Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe cyclosporine capsules, (modified). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe cyclosporine capsules, (modified). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Cyclosporine capsules, (modified), a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients cyclosporine capsules, (modified) may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.
Cyclosporine capsules, (modified) have increased bioavailability in comparison to Sandimmune®Soft Gelatin Capsules (cyclosporine capsules, USP) [NON-MODIFIED]. Cyclosporine capsules, (modified) and Sandimmune®are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with cyclosporine capsules, (modified) than with Sandimmune®. If a patient who is receiving exceptionally high doses of Sandimmune® is converted to cyclosporine capsules, (modified), particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking cyclosporine capsules, (modified) to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed (see Dosage and Administration).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA050790 · Abbvie
- First approved
- December 23, 2002 (24 years ago)
- Latest approved change
- August 21, 2025
- Approved label
- PDF, Aug 26, 2025
- Generic makers
- 13 approved generic applications on the market
- Last patent listed
- May 11, 2034
Cyclosporine questions
How much does cyclosporine cost without insurance?
Pharmacies pay about $27.24 for 30 vials of cyclosporine 0.5 mg/mL, 0.4 mL eye drops (suspension) ($0.9081 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $41.83. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of cyclosporine?
Is cyclosporine in shortage?
No shortage is reported for cyclosporine right now. We check the national shortage list every day.
Has cyclosporine been recalled?
28 recalls on record, 4 ongoing. Recalls name specific lots - check yours.
When did the cyclosporine label last change?
The official label was last updated on November 9, 2026 (version 6). See what changed.
Talk about cyclosporine
No comments yet. Questions, tips, what worked for you - start the conversation.